Silicon Laboratories Inc.

Condensed Consolidated Statements of Cash Flows 

(In thousands) 

(Unaudited)

Nine Months Ended

September 28,
2024

September 30,
2023

Operating Activities

Net income (loss)

$         (167,187)

$             35,271

Adjustments to reconcile net income to net cash used in operating activities:

Depreciation of property and equipment

19,302

18,992

Amortization of other intangible assets

17,596

19,162

Amortization of debt issuance costs

—

960

Stock-based compensation expense

45,358

37,167

Equity-method loss

—

1,150

Deferred income taxes

29,100

(5,881)

Changes in operating assets and liabilities:

Accounts receivable

(19,585)

(30,706)

Inventories

54,724

(66,971)

Prepaid expenses and other assets

23,091

8,085

Accounts payable

(13,849)

(37,039)

Other current liabilities and income taxes

(5,004)

(39,155)

Deferred revenue and returns liability

6,361

3,286

Other non-current liabilities

(13,946)

6,794

Net cash used in operating activities

(24,039)

(48,885)

Investing Activities

Purchases of marketable securities

(28,363)

(91,493)

Sales of marketable securities

44,057

365,073

Maturities of marketable securities

131,008

171,766

Purchases of property and equipment

(7,785)

(18,533)

Proceeds from sale of equity investment

12,382

—

Purchases of other assets

—

(395)

Net cash provided by investing activities

151,299

426,418

Financing Activities

Proceeds from revolving line of credit

—

80,000

Payments on debt

(45,000)

(571,157)

Repurchases of common stock

—

(217,137)

Payment of taxes withheld for vested stock awards

(16,078)

(17,239)

Proceeds from the issuance of common stock

9,396

8,013

Net cash used in financing activities

(51,682)

(717,520)

Increase (decrease) in cash and cash equivalents

75,578

(339,987)

Cash and cash equivalents at beginning of period

227,504

499,915

Cash and cash equivalents at end of period

$           303,082

$           159,928